Home›Trial›NCT04767594
🔬NCT04767594ACTIVE NOT RECRUITING

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Study Summary

This is a prospective, single-arm, multi-center observational non-interventional study (NIS) in Germany and Austria.

Conditions
Breast Neoplasms
Interventions / Drugs
Palbociclib + endocrine therapy
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
F34/100
Study Details
Enrollment1409 participants
Primary Completion—
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.190269+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.